77 related articles for article (PubMed ID: 18845566)
1. PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression.
Chuman Y; Kurihashi W; Mizukami Y; Nashimoto T; Yagi H; Sakaguchi K
J Biochem; 2009 Jan; 145(1):1-12. PubMed ID: 18845566
[TBL] [Abstract][Full Text] [Related]
2. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M; Xu E; Zhang J; Chen X
Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.
Chuman Y; Yagi H; Fukuda T; Nomura T; Matsukizono M; Shimohigashi Y; Sakaguchi K
Protein Pept Lett; 2008; 15(9):938-48. PubMed ID: 18991770
[TBL] [Abstract][Full Text] [Related]
4. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
5. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites.
Rossi M; Demidov ON; Anderson CW; Appella E; Mazur SJ
Nucleic Acids Res; 2008 Dec; 36(22):7168-80. PubMed ID: 19015127
[TBL] [Abstract][Full Text] [Related]
6. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
7. Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A
Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650
[TBL] [Abstract][Full Text] [Related]
8. The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene.
Choi J; Appella E; Donehower LA
Genomics; 2000 Mar; 64(3):298-306. PubMed ID: 10756097
[TBL] [Abstract][Full Text] [Related]
9. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
10. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
Lu X; Nannenga B; Donehower LA
Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
[TBL] [Abstract][Full Text] [Related]
11. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
[TBL] [Abstract][Full Text] [Related]
12. PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development.
Hickson JA; Fong B; Watson PH; Watson AJ
Mol Reprod Dev; 2007 Jul; 74(7):821-34. PubMed ID: 17219434
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Kozakai Y; Kamada R; Kiyota Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2014 Dec; 24(24):5593-5596. PubMed ID: 25466181
[TBL] [Abstract][Full Text] [Related]
14. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
[TBL] [Abstract][Full Text] [Related]
15. Molecular cloning and expression of mouse mg(2+)-dependent protein phosphatase beta-4 (type 2C beta-4).
Kato S; Terasawa T; Kobayashi T; Ohnishi M; Sasahara Y; Kusuda K; Yanagawa Y; Hiraga A; Matsui Y; Tamura S
Arch Biochem Biophys; 1995 Apr; 318(2):387-93. PubMed ID: 7733667
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
17. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
18. Phosphatase assay for multi-phosphorylated substrates using phosphatase specific-motif antibody.
Chuman Y; Iizuka K; Honda T; Onoue H; Shimohigashi Y; Sakaguchi K
J Biochem; 2011 Sep; 150(3):319-25. PubMed ID: 21558087
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines.
Cheeseman MD; Faisal A; Rayter S; Barbeau OR; Kalusa A; Westlake M; Burke R; Swan M; van Montfort R; Linardopoulos S; Jones K
Bioorg Med Chem Lett; 2014 Aug; 24(15):3469-74. PubMed ID: 24953599
[TBL] [Abstract][Full Text] [Related]
20. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Fuku T; Semba S; Yutori H; Yokozaki H
Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
